Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.32
(0.53%)
INR 13.32
(0.53%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.54 Billion INR | 0.81% |
| 2022 | 6.49 Billion INR | 2.76% |
| 2021 | 6.31 Billion INR | -5.93% |
| 2020 | 6.71 Billion INR | 11.62% |
| 2019 | 6.01 Billion INR | 0.54% |
| 2018 | 5.98 Billion INR | -2.34% |
| 2017 | 6.12 Billion INR | -7.79% |
| 2016 | 6.64 Billion INR | -37.0% |
| 2015 | 10.54 Billion INR | -14.09% |
| 2014 | 12.27 Billion INR | -11.65% |
| 2013 | 13.89 Billion INR | -1.25% |
| 2012 | 14.07 Billion INR | -10.25% |
| 2011 | 15.68 Billion INR | 26.75% |
| 2010 | 12.37 Billion INR | 20.57% |
| 2009 | 10.26 Billion INR | 26.08% |
| 2008 | 8.13 Billion INR | 13.46% |
| 2007 | 7.17 Billion INR | 28.55% |
| 2006 | 5.58 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 6.54 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 6.54 Billion INR | 0.81% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 6.39 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 6.22 Billion INR | 0.0% |
| 2022 Q4 | 6.49 Billion INR | 0.0% |
| 2022 FY | 6.49 Billion INR | 2.76% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 6.31 Billion INR | -5.93% |
| 2021 Q4 | 6.31 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 6.49 Billion INR | 0.0% |
| 2020 Q2 | 6.08 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 6.71 Billion INR | 11.62% |
| 2020 Q4 | 6.71 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 6.01 Billion INR | 0.54% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 6.09 Billion INR | 0.0% |
| 2019 Q4 | 6.01 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 5.98 Billion INR | -2.34% |
| 2018 Q4 | 5.98 Billion INR | 0.0% |
| 2017 Q4 | 6.12 Billion INR | 0.0% |
| 2017 FY | 6.12 Billion INR | -7.79% |
| 2016 Q4 | 6.64 Billion INR | 0.0% |
| 2016 FY | 6.64 Billion INR | -37.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 9.64 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 10.54 Billion INR | 0.0% |
| 2015 Q2 | 12.1 Billion INR | 0.0% |
| 2015 FY | 10.54 Billion INR | -14.09% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 12.27 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 FY | 12.27 Billion INR | -11.65% |
| 2014 Q2 | 13.65 Billion INR | 0.0% |
| 2013 Q4 | 13.89 Billion INR | 0.0% |
| 2013 FY | 13.89 Billion INR | -1.25% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 13.72 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q3 | 28.85 Billion INR | 0.0% |
| 2012 Q4 | 14.07 Billion INR | -51.23% |
| 2012 FY | 14.07 Billion INR | -10.25% |
| 2011 FY | 15.68 Billion INR | 26.75% |
| 2010 FY | 12.37 Billion INR | 20.57% |
| 2009 FY | 10.26 Billion INR | 26.08% |
| 2008 FY | 8.13 Billion INR | 13.46% |
| 2007 FY | 7.17 Billion INR | 28.55% |
| 2006 FY | 5.58 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 89.846% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 98.548% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 77.039% |
| Granules India Limited | 55.2 Billion INR | 88.146% |
| Indoco Remedies Limited | 21.44 Billion INR | 69.485% |
| Achyut Healthcare Limited | 309.52 Million INR | -2014.458% |
| Ajanta Pharma Limited | 46.38 Billion INR | 85.89% |
| Alkem Laboratories Limited | 155.74 Billion INR | 95.798% |
| Alpa Laboratories Limited | 1.82 Billion INR | -258.375% |
| Brooks Laboratories Limited | 904.45 Million INR | -623.609% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 39.29% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 14.462% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 46.084% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 98.311% |
| Eris Lifesciences Limited | 70.48 Billion INR | 90.715% |
| FDC Limited | 24.68 Billion INR | 73.483% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 95.442% |
| Gufic Biosciences Limited | 10.92 Billion INR | 40.096% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 43.827% |
| Ipca Laboratories Limited | 111.01 Billion INR | 94.105% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -201.491% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -267.32% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -333.802% |
| Laurus Labs Limited | 83.87 Billion INR | 92.197% |
| Lupin Limited | 239.97 Billion INR | 97.273% |
| Mankind Pharma Limited | 119.63 Billion INR | 94.529% |
| Medicamen Biotech Limited | 2.94 Billion INR | -122.214% |
| Medico Remedies Limited | 961.95 Million INR | -580.357% |
| Megasoft Limited | 3.65 Billion INR | -78.866% |
| NATCO Pharma Limited | 69.06 Billion INR | 90.524% |
| Piramal Pharma Limited | 153.11 Billion INR | 95.726% |
| RPG Life Sciences Limited | 5.12 Billion INR | -27.61% |
| Sigachi Industries Limited | 6.94 Billion INR | 5.717% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.234% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 70.965% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -61.732% |
| Unichem Laboratories Limited | 31.69 Billion INR | 79.35% |
| Wanbury Limited | 3.43 Billion INR | -90.534% |
| Windlas Biotech Limited | 6.26 Billion INR | -4.514% |
| ZIM Laboratories Limited | 4.46 Billion INR | -46.472% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 97.765% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -27.072% |
| Divi's Laboratories Limited | 154.7 Billion INR | 95.769% |
| Hester Biosciences Limited | 6.62 Billion INR | 1.189% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 17.61% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -78.393% |
| Bal Pharma Limited | 3.2 Billion INR | -104.274% |
| Strides Pharma Science Limited | 58.39 Billion INR | 88.793% |
| Venus Remedies Limited | 6.26 Billion INR | -4.41% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 74.654% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 70.13% |
| Shilpa Medicare Limited | 30.93 Billion INR | 78.842% |
| Aarti Drugs Limited | 24.32 Billion INR | 73.093% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 70.84% |
| Suven Life Sciences Limited | 2.84 Billion INR | -129.717% |
| Valiant Laboratories Limited | 3.42 Billion INR | -90.982% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 83.614% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 72.162% |
| Themis Medicare Limited | 5.66 Billion INR | -15.546% |
| Hikal Limited | 24.87 Billion INR | 73.686% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 95.655% |
| Sequent Scientific Limited | 15.4 Billion INR | 57.512% |
| Novartis India Limited | 9.24 Billion INR | 29.241% |
| Wockhardt Limited | 76.49 Billion INR | 91.444% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 94.333% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -1290.046% |
| Neuland Laboratories Limited | 18.32 Billion INR | 64.287% |
| Morepen Laboratories Limited | 12.93 Billion INR | 49.392% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -172.626% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -96.288% |